Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• The HER2 (human epidermal growth factor receptor 2) proto-oncogene encodes a transmembrane receptor tyrosine kinase homologous to the EGF receptor (HER1).
• HER2 overexpression is frequent in breast and ovarian carcinomas, making it a significant therapeutic target.

Purpose of the Study:

• To synthesize and characterize protein tyrosine kinase inhibitors (tyrphostins) that selectively inhibit HER2 kinase activity.
• To explore the potential for discriminating between the highly homologous HER2 and HER1 kinases using small molecules.

Main Methods:

• Synthesis of two groups of tyrphostins: HER1-selective and HER2-selective inhibitors.
• In vitro assessment of inhibitor binding kinetics, specifically competition with ATP binding.
• Evaluation of inhibitor efficacy in blocking mitogenic signaling induced by EGF in NIH3T3 cells overexpressing HER1 or HER1-2.

Main Results:

• Both HER1-selective and HER2-selective tyrphostins were found to be competitive with ATP binding.
• The study successfully designed small molecules capable of discriminating between the highly homologous HER2 and HER1 kinases, indicating differences in their ATP binding sites.
• In cellular assays, agents discriminating between HER1 and HER2 in vitro identically blocked mitogenic signaling, suggesting a potential role for downstream signaling elements.

Conclusions:

• It is feasible to design small molecules that selectively inhibit HER2 kinase activity, despite its high homology with HER1.
• Differences in ATP binding sites between HER2 and HER1 kinases can be exploited for selective inhibition.
• The antiproliferative effects of these tyrphostins may involve the inhibition of downstream tyrosine kinases mediating mitogenic signaling, potentially influenced by intracellular ATP levels.